Session » Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1254

A Retrospective Medical Chart Review of Patients with Periodic Fever Syndromes Initiating Canakinumab in the United States

9:00AM-11:00AM: Abstract Number: 1271

Adult-Onset Still’s Disease Prognosis Score: Clinical Patterns, Complications and Biologic Treatment

9:00AM-11:00AM: Abstract Number: 1247

Adult-Onset Still’s Disease and Spondyloarthritis: Overlapping Syndrome or Incidental Association? A Series of 5 Cases

9:00AM-11:00AM: Abstract Number: 1266

AGBL3 as a Novel Gene Associated with Hereditary Hypocomplementemic Urticarial Vasculitis and Favorable Response to Rituximab

9:00AM-11:00AM: Abstract Number: 1243

Anakinra Treatment in Recurrent Pericarditis: Single Center Experience

9:00AM-11:00AM: Abstract Number: 1272

Biological Therapy in Non Ischaemic Optic Neuritis Associated to Immune-mediated Inflammatory Diseases: Multicenter Study

9:00AM-11:00AM: Abstract Number: 1250

Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease?

9:00AM-11:00AM: Abstract Number: 1273

Certolizumab Therapy in Patients with Uveitis During Pregnancy: Multicenter Study

9:00AM-11:00AM: Abstract Number: 1262

Clinical Features of Elderly-onset Adult Still’s Disease

9:00AM-11:00AM: Abstract Number: 1248

Clinical Manifestations and Management of US Patients with SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) Syndrome, a Retrospective Study

9:00AM-11:00AM: Abstract Number: 1256

Comparison of FMF Patients with Age of Onset Before 20 versus 40 Years and Over

9:00AM-11:00AM: Abstract Number: 1268

Different Colchicine Preparations for Familial Mediterranean Fever: Are They the Same?

9:00AM-11:00AM: Abstract Number: 1269

Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome

9:00AM-11:00AM: Abstract Number: 1270

Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study

9:00AM-11:00AM: Abstract Number: 1258

Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial

9:00AM-11:00AM: Abstract Number: 1245

Efficacy of Canakinumab Treatment in Adult-onset Still’s Disease

9:00AM-11:00AM: Abstract Number: 1267

Epidemology, Clinical Features and Relationship to Biological Therapy of Uveitis in Axial Spondyloarthritis: Single Center University Study

9:00AM-11:00AM: Abstract Number: 1241

Further Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis of Morphea in Adults and Children

9:00AM-11:00AM: Abstract Number: 1242

Impact of Smoking Status on Remission in Hidradenitis Suppurativa

9:00AM-11:00AM: Abstract Number: 1255

Is Exon 2 Associated with FMF or a New Disease?

9:00AM-11:00AM: Abstract Number: 1265

Mandibular Involvement in SAPHO Syndrome: A Single-center Retrospective Study of 26 Patients

9:00AM-11:00AM: Abstract Number: 1253

Novel Nonsense Variant and Entire Deletion of TNFAIP3 Cause Haploinsufficiency of A20 Clinically Distinct from Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1252

Pattern of Arthropathy in Patients with Cystic Fibrosis

9:00AM-11:00AM: Abstract Number: 1249

Pelvic Congestion Syndrome, an Uncommon Cause of Osteoarticular Pain

9:00AM-11:00AM: Abstract Number: 1264

Quality of Life in Patients with SAPHO Syndrome: A Single-center Survey of 588 Patients

9:00AM-11:00AM: Abstract Number: 1257

Recommendation on Colchicine Dosing and Definition of Colchicine Resistance/Intolerance in the Management of Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 1259

Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO): A Case Series

9:00AM-11:00AM: Abstract Number: 1251

The Impact of Aging on Familial Mediterranean Fever Patients

9:00AM-11:00AM: Abstract Number: 1263

The Prevalence and Patterns of Celiac Disease Associated Arthropathy and Coexistence of Celiac Disease with Rheumatic Disorders in a Single Tertiary Medical Center

9:00AM-11:00AM: Abstract Number: 1260

The Study of Peripheral Blood Lymphocyte Subsets and CD4+T Subsets in Recurrent Polychondritis

9:00AM-11:00AM: Abstract Number: 1261

The Time Lag – the Race in Diagnosis and Management of Hemophagocytic Lymphohistiocytosis

9:00AM-11:00AM: Abstract Number: 1244

Tocilizumab – An Effective Rescue Therapy for Refractory Unclassified Autoinflammatory Diseases in Children

9:00AM-11:00AM: Abstract Number: 1246

Using PROMIS Data to Assess Activity of Inflammatory Eye Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].